# A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

> **NCT04157517** · PHASE1,PHASE2 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D LLC** · enrollment: 45 (actual)

## Conditions studied

- Neoplasms
- Melanoma

## Interventions

- **DRUG:** Modakafusp Alfa
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04157517
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-12
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Study was terminated early due to futility.
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157517, "A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04157517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*